脳動静脈奇形と動脈瘤を伴う症例:疫学、臨床的特徴、および予後
脳動静脈奇形および頭蓋内動脈瘤患者における血行動態機構、臨床プロファイル、予後因子:観察コホート研究
The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.
調査の概要
状態
状態
詳細な説明
This study aims to evaluate the clinical safety and efficacy of different treatment strategies in patients with cerebral arteriovenous malformations (AVMs) combined with intracranial aneurysms (IAs) through a multicenter, large-sample, prospective observational cohort study. It will comprehensively analyze the epidemiological characteristics, clinical manifestations, associated risk factors, natural disease progression, and bleeding risks, as well as explore the hemodynamic mechanisms and genetic background differences. Clinical data, imaging findings, and blood samples will be collected from patients to investigate the impact of hemodynamics on aneurysm formation, rupture risk, and treatment outcomes. Additionally, the study will explore the genetic differences of AVM and IA patients and their correlation with clinical presentation and prognosis, ultimately providing a scientific basis for individualized treatment strategies.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Xin Feng, MD
- 電話番号:+86 13681134001
- メール:13681134001@163.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、528400
- 募集
- Zhujiang Hospital, Southern Medical University
-
コンタクト:
- Xin Feng, MD
- 電話番号:+86 13681134001
- メール:13681134001@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients treated across eight neurosurgery centers who were confirmed by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), computed tomographic angiography (CTA) to have cerebral arteriovenous malformation and intracranial aneurysm.
説明
Inclusion Criteria:
- Patients diagnosed with cerebral arteriovenous malformation and intracranial aneurysm confirmed by CTA, MRA, and/or DSA;
- Availability of complete clinical and imaging data;
- Provision of written informed consent by the patient or their legally authorized representative to participate in the study and undergo follow-up;
- Not concurrently participating in any other clinical trials that may interfere with the outcomes of this study.
Exclusion Criteria:
- Previous complete occlusion of the aneurysm and/or arteriovenous malformation prior to enrollment;
- Coexistence of other cerebrovascular diseases such as moyamoya disease, cerebral cavernous malformation, cerebral venous sinus thrombosis, etc.;
- Absence of DSA imaging data or poor image quality that precludes accurate evaluation of key anatomical and hemodynamic parameters of the AVM and intracranial aneurysm.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Patients diagnosed with cerebral arteriovenous malformations and intracranial aneurysms
Patients diagnosed with concomitant cerebral arteriovenous malformations and intracranial aneurysms by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), and/or computed tomographic angiography (CTA). |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Imaging Treatment Success Rate of Target Vascular Lesions
時間枠:3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively
|
his is a composite endpoint with stratified reporting by lesion type. It will separately calculate and report the success rates for the following two patient cohorts: For patients with intracranial aneurysms: Treatment success is defined as complete occlusion on postoperative digital subtraction angiography, assessed as Class I by the Raymond-Roy Occlusion Classification (RROC) or as Grade D by the O'Kelly-Marotta (OKM) grading scale. For patients with cerebral arteriovenous malformations (AVMs): Treatment success is defined as complete embolization on postoperative digital subtraction angiography, confirmed by the core laboratory or two independent assessors with no residual nidus opacification. Critical clarification: This composite measure does NOT calculate an overall arithmetic combined success rate. The final reported values will be two independent percentages. |
3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of perioperative complications
時間枠:Perioperative period
|
Perioperative complications include technical related complications (vascular rupture, thrombosis, etc.) and clinical complications (neurological deficits, infections, etc.) |
Perioperative period
|
|
Proportion of patients with hemorrhagic complications during follow-up period
時間枠:within three years
|
Including the type of bleeding (intracerebral hemorrhage/subarachnoid hemorrhage/intraventricular hemorrhage), specific location of bleeding,amount of bleeding;and determination of bleeding source: determine the source of bleeding from malformation or aneurysm through imaging examination. |
within three years
|
|
Proportion of patients with poor functional prognosis
時間枠:3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
mRS score 3-6 |
3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
|
Proportion of patients with good functional prognosis
時間枠:3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
mRS score 0-2 |
3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Chuanzhi Duan, MD、Zhujiang Hospital
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- LC2016ZD032
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。